학술논문
An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma
Document Type
article
Author
Stephanie M. Casillo; Taylor A. Gatesman; Akanksha Chilukuri; Srinidhi Varadharajan; Brenden J. Johnson; Daniel R. David Premkumar; Esther P. Jane; Tritan J. Plute; Robert F. Koncar; Ann-Catherine J. Stanton; Carlos A.O. Biagi-Junior; Callie S. Barber; Matthew E. Halbert; Brian J. Golbourn; Katharine Halligan; Andrea F. Cruz; Neveen M. Mansi; Allison Cheney; Steven J. Mullett; Clinton Van’t Land; Jennifer L. Perez; Max I. Myers; Nishant Agrawal; Joshua J. Michel; Yue-Fang Chang; Olena M. Vaske; Antony MichaelRaj; Frank S. Lieberman; James Felker; Sruti Shiva; Kelsey C. Bertrand; Nduka Amankulor; Costas G. Hadjipanayis; Kalil G. Abdullah; Pascal O. Zinn; Robert M. Friedlander; Taylor J. Abel; Javad Nazarian; Sriram Venneti; Mariella G. Filbin; Stacy L. Gelhaus; Stephen C. Mack; Ian F. Pollack; Sameer Agnihotri
Source
Cell Reports, Vol 43, Iss 1, Pp 113557- (2024)
Subject
Language
English
ISSN
2211-1247
Abstract
Summary: Metabolic reprogramming in pediatric diffuse midline glioma is driven by gene expression changes induced by the hallmark histone mutation H3K27M, which results in aberrantly permissive activation of oncogenic signaling pathways. Previous studies of diffuse midline glioma with altered H3K27 (DMG-H3K27a) have shown that the RAS pathway, specifically through its downstream kinase, extracellular-signal-related kinase 5 (ERK5), is critical for tumor growth. Further downstream effectors of ERK5 and their role in DMG-H3K27a metabolic reprogramming have not been explored. We establish that ERK5 is a critical regulator of cell proliferation and glycolysis in DMG-H3K27a. We demonstrate that ERK5 mediates glycolysis through activation of transcription factor MEF2A, which subsequently modulates expression of glycolytic enzyme PFKFB3. We show that in vitro and mouse models of DMG-H3K27a are sensitive to the loss of PFKFB3. Multi-targeted drug therapy against the ERK5-PFKFB3 axis, such as with small-molecule inhibitors, may represent a promising therapeutic approach in patients with pediatric diffuse midline glioma.